Orphazyme A/S - American Depositary Shares (NQ:ORPH)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 30, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Orphazyme A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >

TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

September 02, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

September 01, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

NASDAQ:ORPH Investor Notice: Deadline on September 7, 2021 in Lawsuit Against Orphazyme A/S ↗

August 26, 2021

San Diego, CA -- (SBWIRE) -- 08/26/2021 -- The Shareholders Foundation announced that a deadline is coming up on September 7, 2021 in the lawsuit filed for certain investors of Orphazyme A/S...

Via SBWire

Topics Lawsuit

CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C

August 24, 2021

From CytRx Corporation

Via Business Wire

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Earnings Scheduled For August 24, 2021 ↗

August 24, 2021

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is likely to report earnings for its second quarter. • Genetron Holdings (NASDAQ:GTH) is...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

Dear ORPH Stock Fans, Here Is the Latest Trial News You Should Be Cheering ↗

August 23, 2021

Today, ORPH stock is trading significantly higher after the company announced some positive clinical trial data for its lead drug candidate.

Via InvestorPlace

Investors React Positively To Data From Orphazyme's Neurodegenerative Disease Candidate ↗

August 23, 2021

Orphazyme A/S (NASDAQ: ORPH) announced that results from a Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C (NPC) had been published in the peer-...

Via Benzinga

66 Biggest Movers From Yesterday ↗

August 12, 2021

Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share. Dyadic...

Via Benzinga

Topics Initial Public Offering

What's Next For Orphazyme Stock? ↗

August 11, 2021

Orphazyme A S ADR (NASDAQ: ORPH) shares are higher Wednesday, as traders were able to push the stock up. There looks to be no company-specific news to cause the jump in share...

Via Benzinga

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

Dear ORPH Stock Fans, Mark Your Calendars for August 31 ↗

August 10, 2021

Today, investors appear to be pricing some positive news and a potential short squeeze into ORPH stock, as Orphazyme shoots higher.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

August 05, 2021

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low...

Via Benzinga

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗

August 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

August 04, 2021

Wednesday's morning session saw 58 companies set new 52-week lows. Noteworthy Mentions: The company with the largest market cap to set a new 52-week low was...

Via Benzinga

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investors With Losses Exceeding $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH

August 02, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

NASDAQ: ORPH Investor Notice: Lawsuit Alleges Securities Laws Violations by Orphazyme A/S ↗

July 28, 2021

San Diego, CA -- (SBWIRE) -- 07/28/2021 -- A lawsuit was filed on behalf of investors in Orphazyme A/S (NASDAQ: ORPH) shares over alleged securities laws violations.

Via SBWire

Topics Lawsuit

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)

July 21, 2021

From Law Offices of Howard G. Smith

Via Business Wire

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)

July 20, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

ORPH Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Orphazyme A/S Shareholders of Class Action and Encourages Shareholders to Contact the Firm

July 19, 2021

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investors With Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH

July 17, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors

July 17, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors

July 16, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors

July 16, 2021

From Law Offices of Howard G. Smith

Via Business Wire

SHAREHOLDER ALERT: Robbins LLP Announces that Orphazyme A/S (ORPH) is Being Sued for Misleading Shareholders

July 16, 2021

From Robbins LLP

Via Business Wire

Orphazyme Stock Is a Dead-End for Investors After FDA Rejection ↗

July 16, 2021

ORPH stock has a virtually impossible task ahead of it in picking itself after FDA's rejection of the Danish biopharma's Arimoclomol drug.

Via InvestorPlace

The Law Offices of Frank R. Cruz Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors

July 15, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.